hVIVO PLC on Monday said that Cidara Therapeutics Inc has seen positive results from an ongoing study testing CD388, a drug designed to treat seasonal flu.

hVIVO is a London-based specialist contract research organisation providing testing for infectious and respiratory vaccines. Cidara is a San Diego, California-based biotherapeutics company.

Cidara has reported positive interim results from an ongoing study testing CD388, which hVIVO is conducting using its H3N2 influenza human challenge study model.

CD388 is Cidara’s long-acting drug-Fc conjugate antiviral for the treatment of seasonal influenza.

The interim analysis is based on 56 healthy volunteers, with 28 receiving a single 150 microgram dose of CD388 and 28 receiving a placebo.

Results showed a decrease in viral replication in the upper respiratory tract and influenza infection in participants receiving a single dose of CD388 when compared to the placebo.

The drug was well-tolerated, with no drug-related adverse events observed.

‘The results are another clear demonstration of the value of human challenge trials in delivering quick efficacy data, de-risking entry into later stage clinical development. Importantly, the data underlined the potential of Cidara’s Cloudbreak drug-Fc conjugates, of which CD388 is one example, to be efficacious long-acting therapeutics with universal protection of seasonal and pandemic influenza,’ said hVIVO’s chief scientific officer, Andrew Catchpole.

hVIVO shares were trading 6.2% higher at 15.50 pence each in London on Monday at noon.

Copyright 2023 Alliance News Ltd. All Rights Reserved.